China Botanic Pharmaceutical Inc. Announces Acceptance of its Plan of Compliance by NYSE MKT LLC

    China Botanic Pharmaceutical Inc. Announces Acceptance of its Plan of
                          Compliance by NYSE MKT LLC

PR Newswire

HARBIN, China, March 7, 2013

HARBIN, China, March 7, 2013 /PRNewswire/ -- China Botanic Pharmaceutical Inc.
(NYSE MKT: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or
the "Company"), a developer, manufacturer and distributor of botanical
products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in
China, announced today that on March 1, 2013, the Company received notice from
the staff of NYSE MKT LLC (the "Exchange") advising the Company that the plan
of compliance previously submitted to the Exchange had been accepted with a
compliance date of May 1, 2013.

Previously the Company disclosed that it had received a notice of failure to
satisfy continued listing standards from the Exchange stating that it was not
in compliance with Sections 134 and 1101 of the NYSE MKT LLC Company Guide as
a result of the Company's inability to timely file its Annual Report on Form
10-K for the period ended October 31, 2012. The Company was afforded an
opportunity to submit a plan of compliance to the Exchange, and on February
14, 2013 the Company presented its plan to the Exchange. On March 1, 2013, the
Exchange notified the Company that it accepted the Company's plan of
compliance and granted the Company an extension until May 1, 2013 to regain
compliance with the continued listing standards. The Company will remain
listed and will be subject to the periodic review by the staff of the Exchange
during the extension period. Failure to make progress consistent with the plan
or to regain compliance with the continued listing standards by May 1, 2013
could result in the Company being delisted from the Exchange. The Company
continues its efforts to execute the plan within the time frame prescribed by
the Exchange.

Trading in the Company's shares remains suspended.

About China Botanic Pharmaceutical Inc.

China Botanic Pharmaceutical Inc. is engaged in the research, development,
manufacturing, and distribution of botanical products, bio-pharmaceutical
products, and traditional Chinese medicines ("TCM"), in the People's Republic
of China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The
Company distributes its botanical anti-depression and nerve-regulation
products, biopharmaceutical products, and botanical antibiotic and OTC TCMs
through its network of over 3,000 distributors and over 70 sales centers
across 24 provinces in China. For more information, please visit
www.renhuang.com.

Safe Harbor Statement

This press release contains certain statements that may include
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are based upon management's
beliefs, assumptions and expectations of the Company's future operations and
financial performance, taking into account the information currently available
to management. These statements are not statements of historical fact.
Forward-looking statements involve risks and uncertainties, some of which are
not currently known that may cause actual results, performance or financial
condition to be materially different from the expectations of future results,
performance or financial condition expressed or implied in any forward-looking
statements. These forward-looking statements are based on current plans and
expectations and are subject to a number of uncertainties including, butnot
limited to, the Company's ability to manage expansion of its operations
effectively, and other factors detailed in the Company's annual report on Form
10-K and other filings with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information presented herein.

Company Contact:

China Botanic Pharmaceutical Inc.
Ms. Portia Tan, IR Contact
Tel: 86-451-8260-2162
Email: ir@renhuang.com

SOURCE China Botanic Pharmaceutical Inc.

Website: http://www.renhuang.com